![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to fund a preclinical study on Glioblastoma (GBM), an incurable brain cancer, to potentially increase the efficacy of Merck's FDA approved drug Temodar (temozolomide).
Lead Product(s): Temozolomide
Therapeutic Area: Oncology Product Name: Temodar
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: University of Central florida
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing March 27, 2024
Details:
NuGenea is a nutraceutical formulated with 20 different ingredients which have been scientifically shown to help fight chronic inflammation, which is a causative factor in illnesses such as cancer, diabetes, COPD and heart disease.
Lead Product(s): Amino Acids Mixture
Therapeutic Area: Immunology Product Name: NuGenea
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2023
Details:
Bacillus Calmette-Guérin (BCG) is a cancer vaccine that uses weakened bacteria to stimulate the immune system. BCG (mycobacterium bovis bacille calmette-guerin vaccine) has received U.S. FDA approval for the treatment of early-stage bladder cancer.
Lead Product(s): Mycobacterium Bovis Bacille Calmette-guerin Vaccine
Therapeutic Area: Oncology Product Name: BCG
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Emerson Urology Associates
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022